AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
ProQR Therapeutics BV (NASDAQ:PRQR)
2.3208 USD
+0.161 7.444%Sponsored Reports
Loading...
| Previous Close (in USD) | 2.16 |
|---|---|
| Change | +0.161 7.444% |
| 52 W H/L (in USD) | 3.290/1.110 |
| EBITDA (in USD) | -32.654M |
| PE Ratio | -- |
| Volume | 666693 |
| Diluted Eps TTM | -0.36 |
| Total Assets (in USD) | 137.997M |
|---|---|
| Total Liabilities (in USD) | 96.573M |
| Revenue TTM (in USD) | 10.557M |
| Cash (in USD) | 119.023M |
| Market Cap (in USD) | 153.525 M |
| Revenue Per Share TTM | 0.130 |
| Gross Profit TTM (in USD) | 4.802M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Employees: 156
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Domenico Valerio Ph.D. | Founder & Independent Chairman of Supervisory Board | 1956 |
| 2. | Mr. Daniel Anton de Boer | Founder, CEO & Member of Management Board | 1983 |
| 3. | Dr. Gerard Platenburg | Co-Founder & Chief Scientific Officer | 1964 |
| 4. | Mr. Jurriaan Dekkers | Chief Financial Officer | NA |
| 5. | Mr. Rene K. Beukema | Chief Corp. Devel. Officer, Gen. Counsel & Member of Management Board | 1964 |
| 6. | Ms. Sheila Sponselee | VP & Head of People and Operations | NA |
| 7. | Ms. Sarah Cue Kiely | VP of Investor Relations & Corp. Communications | NA |
| 8. | Mr. Bart Klein | Sr. VP of Intellectual Property | NA |
| 9. | Mr. Aniz Girach M.D. | Chief Medical Officer | 1967 |
| 10. | Ms. Sandra van der Kolk | Jr. Financial Controller | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.070 1.581% | 68.76 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+2.420 3.640% | 68.9 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+2.740 0.618% | 442.99 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.606 0.500% | 521.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -64.795M | -61.563M | -46.49M | -56.614M | -37.085M |
| Minority Interest | -0.22M | 0.059M | -0.545M | -0.496M | -0.23M |
| Net Income | -64.891M | -61.68M | -46.614M | -56.746M | -36.894M |
| Selling General Administrative | 18.651M | 17.368M | 13.685M | 12.887M | 12.54M |
| Gross Profit | 4.037M | 1.354M | - | -114.89M | 4.941M |
| Reconciled Depreciation | 2.521M | 2.329M | 2.355M | 2.052M | 0.992M |
| Ebit | -64.716M | -57.191M | -42.368M | -57.445M | -42.054M |
| Ebitda | -59.384M | -55.376M | -49.465M | -57.326M | -41.062M |
| Depreciation And Amortization | 5.332M | 1.815M | -7.097M | 0.119M | 0.992M |
| Operating Income | -64.716M | -57.191M | -42.368M | -57.445M | -36.293M |
| Other Operating Expenses | 68.753M | 58.545M | 51.82M | 59.378M | 42.054M |
| Interest Expense | 5.127M | 3.405M | 2.04M | 1.083M | 0.81M |
| Tax Provision | 0.096M | 0.117M | 0.124M | 0.132M | 0.001M |
| Interest Income | 0.106M | 0.005M | 0.313M | 0.763M | 0.189M |
| Net Interest Income | -5.021M | -2.789M | -3.716M | -0.32M | -0.621M |
| Income Tax Expense | 0.096M | 0.117M | 0.124M | 0.132M | 0.001M |
| Total Revenue | 4.037M | 1.354M | 0M | 1.933M | 4.941M |
| Total Operating Expenses | 68.753M | 58.545M | 51.82M | 59.378M | 42.054M |
| Cost Of Revenue | - | - | - | 116.823M | 0M |
| Total Other Income Expense Net | -0.079M | -4.372M | -4.122M | 0.831M | 5.761M |
| Net Income From Continuing Ops | -64.891M | -61.68M | -46.614M | -56.746M | -37.086M |
| Net Income Applicable To Common Shares | -65.111M | -61.621M | -46.565M | -56.48M | -36.894M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 137.997M | 171.321M | 209.579M | 98.729M | 117.535M |
| Intangible Assets | - | - | - | - | 0M |
| Other Current Assets | 0.794M | - | 3.136M | 3.383M | 1.526M |
| Total Liab | 96.573M | 106.208M | 96.35M | 42.183M | 23.702M |
| Total Stockholder Equity | 41.424M | 65.497M | 113.833M | 57.091M | 94.329M |
| Other Current Liab | 10.488M | 11.068M | 15.985M | 6.985M | 8.986M |
| Common Stock | 3.373M | 3.37M | 2.995M | 2.165M | 2.159M |
| Capital Stock | 3.37M | 3.37M | 2.995M | 2.165M | 2.159M |
| Retained Earnings | -401.18M | -380.677M | -317.77M | -257.747M | -211.746M |
| Good Will | - | - | - | - | 0M |
| Other Assets | - | - | - | - | 0M |
| Cash | 119.023M | 94.775M | 187.524M | 75.838M | 111.95M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 34.231M | 21.112M | 27.596M | 10.301M | 10.993M |
| Current Deferred Revenue | 20.586M | 5.765M | 5.115M | 0.7M | 0.711M |
| Net Debt | -99.273M | -72.804M | -127.152M | -41.561M | -98.39M |
| Short Term Debt | 1.615M | 3.887M | 6.305M | 2.395M | 0.851M |
| Short Long Term Debt | - | 2.5M | 4.771M | 1.135M | 0.343M |
| Short Long Term Debt Total | 19.75M | 21.971M | 60.372M | 34.277M | 13.56M |
| Other Stockholder Equity | 413.234M | 412.54M | 398.309M | 312.862M | 303.765M |
| Property Plant Equipment | - | 16.24M | 17.467M | 18.601M | 2.44M |
| Total Current Assets | 121.086M | 154.46M | 191.483M | 80.021M | 114.666M |
| Long Term Investments | 0M | 0.621M | 0.629M | 0.107M | 0.429M |
| Short Term Investments | - | - | - | - | 0M |
| Net Receivables | 1.269M | 57.236M | 0.555M | 0.421M | 0.85M |
| Long Term Debt | 4.292M | 4.271M | 39.319M | 16.189M | 12.709M |
| Inventory | 0M | - | 0.268M | - | 0M |
| Accounts Payable | 1.542M | 0.392M | 0.191M | 0.221M | 0.445M |
| Accumulated Other Comprehensive Income | 25.997M | 30.264M | 30.299M | -0.189M | 0.151M |
| Non Currrent Assets Other | - | - | - | - | -1.368M |
| Non Current Assets Total | 16.911M | 16.861M | 18.096M | 18.708M | 2.869M |
| Capital Lease Obligations | 15.442M | 15.2M | 16.282M | 16.953M | 0.508M |
| Long Term Debt Total | - | - | - | - | 12.709M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.702M | -0.425M | -0.924M | -0.58M | -0.312M |
| Total Cashflows From Investing Activities | -0.702M | -0.425M | -0.924M | -0.58M | -0.312M |
| Total Cash From Financing Activities | -30.89M | 136.832M | 14.5M | 50.199M | 88.646M |
| Net Income | -64.891M | -61.68M | -46.614M | -56.746M | -37.086M |
| Change In Cash | -92.749M | 111.686M | -36.112M | 6.37M | 57.481M |
| Begin Period Cash Flow | 187.524M | 75.838M | 111.95M | 105.58M | 48.099M |
| End Period Cash Flow | 94.775M | 187.524M | 75.838M | 111.95M | 105.58M |
| Total Cash From Operating Activities | -68.508M | -26.012M | -47.06M | -43.97M | -30.682M |
| Depreciation | 2.521M | 2.329M | 2.355M | 2.052M | 0.992M |
| Other Cashflows From Investing Activities | - | - | - | 0M | 0M |
| Dividends Paid | - | - | - | 0M | 0M |
| Change To Inventory | - | - | - | 0M | 0M |
| Sale Purchase Of Stock | - | - | - | 48.743M | 85.061M |
| Other Cashflows From Financing Activities | 0.034M | 29.175M | 15.105M | 2.91M | 2.266M |
| Capital Expenditures | 0.708M | 0.484M | 0.924M | 0.58M | 0.312M |
| Change In Working Capital | -5.434M | 24.995M | -5.011M | 1.783M | 1.294M |
| Other Non Cash Items | -3.669M | 2.011M | -5.752M | -0.402M | 0.792M |
| Free Cash Flow | -69.216M | -26.496M | -47.984M | -44.55M | -30.994M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Beleggingsfonds Hoofbosch | 1 year ago | 800000 |
| 2. | Delaware Healthcare I | 1 year ago | 620000 |
| 3. | Xtrackers MSCI World Swap ETF 1C | 1 year ago | 328305 |
| 4. | Xtrackers S&P 500 Swap ETF 1C | 1 year ago | 56844 |
| 5. | Fidelity Nasdaq Composite Index | 1 year ago | 46671 |
| 6. | Northern Small Cap Core K | 1 year ago | 6172 |
| 7. | Blackstone Alternative Multi-Strategy I | 1 year ago | 4200 |
| 8. | NT Quality Small Cap Core | 1 year ago | 3795 |
| 9. | NT Quality SCC US Fund - L | 1 year ago | 3795 |
| 10. | LUX IM Global Medtech HX | 1 year ago | 1612 |
| 11. | Avantis International Small Cp Eq ETF | 1 year ago | 185 |
| 12. | Lazard Genetic Therapies ADR | 1 year ago | 103 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Privium Fund Management B.V. | 1 year ago | 5344446 |
| 2. | Adage Capital Partners Gp LLC | 1 year ago | 3625467 |
| 3. | EcoR1 Capital, LLC | 1 year ago | 2884357 |
| 4. | M28 Capital Management LP | 1 year ago | 1019498 |
| 5. | Dafna Capital Management LLC | 1 year ago | 905582 |
| 6. | Macquarie Group Ltd | 1 year ago | 620000 |
| 7. | Ikarian Capital, LLC | 1 year ago | 483583 |
| 8. | Deutsche Bank AG | 1 year ago | 385208 |
| 9. | Millennium Management LLC | 1 year ago | 328989 |
| 10. | Monaco Asset Management | 1 year ago | 312629 |
| 11. | Two Sigma Advisers, LLC | 1 year ago | 162000 |
| 12. | Squarepoint Ops LLC | 1 year ago | 152502 |
| 13. | Franklin Street Advisors Inc. | 1 year ago | 150000 |
| 14. | Morgan Stanley - Brokerage Accounts | 1 year ago | 113711 |
| 15. | BOOTHBAY FUND MANAGEMENT, LLC | 1 year ago | 95745 |
| 16. | Two Sigma Investments LLC | 1 year ago | 78944 |
| 17. | Bank of America Corp | 1 year ago | 78253 |
| 18. | Geode Capital Management, LLC | 1 year ago | 46671 |
| 19. | Resources Investment Advisors Inc | 1 year ago | 31950 |
| 20. | Bank of Montreal | 1 year ago | 30000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...